

Media Coverage

Online: India brand Equity Foundation, Mumbai/Ahmedabad - 2nd December, 2009

Troikaa gets Australian patent for Dynapar AQ

Mumbai/Ahmedabad: Troikaa Pharmaceuticals Ltd, an Ahmedabad based healthcare company, has been granted patent in Australia for its novel drug delivery form of Diclofenac injections, Dynapar AQ, the world's first painless pain-killer injection.

The company sought global protection for its product by filing a Patent Cooperation Treaty(PCT) application with the World Intellectual Property Organisation (WIPO). Subsequently, the company filed for global patents in 99 countries, which included regulated as well as non-regulated countries.

Speaking about the patent approval, Ketan Patel, managing director, Troikaa Pharmaceuticals Ltd, said "The Australian patent is the first one granted among regulated countries. We are also expecting patent approvals in the United States, EU and Canada within the next few weeks. The company has spent about Rs 3 crores on this endeavour but will reap manifold dividends in return."

Diclofenac injections are used for management of painful inflammatory conditions. Dynapar AQ is a unique high concentration, low viscosity injection of diclofenac sodium delivering the full therapeutic dose of diclofenac in just one millilitre injection volume. It is the only diclofenac injection available in PFS (pre-filled syringe) form.

Compared to conventional diclofenac injections, Dynapar AQ causes negligible pain and can be injected in the upper arm, unlike the conventional one injected in the buttocks. Also, Dynapar AQ produces higher blood levels as compared to conventional diclofenac injection, thereby providing superior anti-inflammatory action. Dynapar AQ Injection is ranked second in the highly competitive diclofenac injections category on ORG-IMS and slated to become the top brand by mid-2010.

The company holds patented technology platforms for various Novel Drug Delivery Systems, Intra-oral, Oral, Parenteral, Sustain Release & Topical.

It has manufacturing facilities located in Ahmedabad and Dehradun (Uttaranchal). The Ahmedabad facility located at Thol, an industrial area 25 kilometers from the city and manufactures high quality Critical Care Injectables, Tablets and Topical preparations.
